Skip to content

The Effect of Prematurity and Hypertensive Disorders of Pregnancy on Offspring Cardiovascular Health

The Effect of Prematurity and Hypertensive Disorders of Pregnancy on Offspring Cardiovascular Health

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01888770
Acronym
EPOCH
Enrollment
300
Registered
2013-06-28
Start date
2011-08-31
Completion date
2017-09-30
Last updated
2016-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preeclampsia, Preterm Birth

Brief summary

The purpose of this study is to investigate whether exposure to hypertensive disorders of pregnancy and/or a preterm birth results in alterations in the cardiovascular system during infancy.

Detailed description

While the incidence of cardiovascular disease has reduced dramatically, coinciding with favourable changes in risk factors, cardiovascular disease remains the single largest cause of mortality and premature mortality in the United Kingdom. Identification of novel biological pathways that underlie disease susceptibility raises the potential for new early primary prevention strategies to complement classical management. There is particular interest in the role of early environment in 'programming' risk of cardiovascular disease in later life and growing evidence that various early life exposures impact cardiovascular health in the longer term. The investigators have therefore designed the EPOCH study to investigate whether those individuals born to hypertensive pregnancies and/or to a preterm birth demonstrate differences in the cardiovascular phenotype at birth, or whether they develop any differences over the first three months of life and whether this varies with other perinatal factors. This study also allows investigation of the short term impact of perinatal interventions used in this cohort. Comprehensive multi-modality non-invasive imaging measures of cardiovascular structure and function allow precise quantification of cardiovascular phenotype in this population.

Interventions

None listed

Sponsors

British Heart Foundation
CollaboratorOTHER
University of Oxford
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 6 Months
Healthy volunteers
No

Inclusion criteria

* Available for assessment within the neonatal period, * Parent is willing and able to give informed consent for participation in the study, * Physical condition is suitable to allow non-invasive vascular testing, * Mother meets criteria for inclusion in the study and is willing to participate in the study. (Aged \>/= 16 years and Is able and willing to give informed consent for participation in the study, and is able and willing to give informed consent for her infants participation in the study. ) * Cases: Diagnosed during pregnancy with preeclampsia or gestational hypertension and/or delivered preterm (\<37 weeks gestation) * Controls: No history of gestational hypertension or preeclampsia during this pregnancy and delivered at term (\>37 weeks gestation)

Exclusion criteria

* Parent is unwilling to give consent, * Unavailable for assessment of cardiovascular system, * Physical condition unsuitable to allow for non-invasive testing of cardiovascular system, * Evidence of congenital cardiovascular disease (with the exception of Persistent Patent Ductus Arterious (PDA) and Atrial Septal Defect (ASD)), * Cardiorespiratory instability at time of proposed measures, * Active infection at time of proposed study measures, * Mother of infant is excluded from the study. (Aged \<16 years, unable or unwilling to consent to study or Physical condition post delivery such that it would preclude participation in the study)

Design outcomes

Primary

MeasureTime frameDescription
Systolic Cardiac FunctionBirth and 3 monthsCardiac Function will be assessed by ECHO at birth and 3 months

Secondary

MeasureTime frameDescription
Pulse wave velocity and pulse-wave analysisBirth and 3 months
Cardiac StructureBirth and 3 monthsCardiac structure will be assessed by echocardiography at in utero, at birth and 3 months (as left and right ventricular mass)
Micro-vascular StructureBirth and 3 monthsMicro-vascular Structure will be assessed using Side Stream Dark Field (SDF) imaging device at birth and 3 months (as capillary density at baseline)
Blood pressureBirth and 3 months
Heart rate variabilityBirth and 3 monthsHeart rate variability will be assessed by a 5 minute electrocardiogram
Cardiac diastolic functionBirth and 3 monthsCardiac Function will be assessed by ECHO at birth and 3 months

Countries

United Kingdom

Contacts

Primary ContactPaul Leeson, PhD, FRCP
paul.leeson@cardiov.ox.ac.uk+44(0)1865572846

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026